StockNews.AI
NGNE
StockNews.AI
196 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

1. Pomerantz LLP investigates claims for Neurogene investors regarding possible securities fraud. 2. Neurogene's NGN-401 therapy reported serious adverse events in clinical trials. 3. Stock price fell 44.08% after adverse trial news affecting investor sentiment. 4. Another update revealed a patient's critical condition, further impacting stock negatively.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Negative clinical trial results and ongoing investigations can severely undermine investor confidence. Historical examples show significant stock declines for companies facing legal scrutiny post-adverse results.

How important is it?

The ongoing investigation and serious adverse events are critical for investor considerations. Legal implications and negative sentiment from clinical data directly impact NGNE's market performance.

Why Short Term?

Immediate investor reactions to news can lead to rapid price drops. As current investigations unfold, volatility may continue.

Related Companies

NGNEAAVRett syndrome
NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Neurogene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On November 11, 2024, Neurogene issued a press release reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome."  Although Neurogene characterized the data as "positive", one of two patients given a high dose reported an emerging treatment-related serious adverse event that the Company described as "consistent with known risks of [adeno-associated virus] gene therapy[.]" On this news, Neurogene's stock price fell $31.53 per share, or 44.08%, to close at $40.00 per share on November 12, 2024. Then, on November 18, 2024, Neurogene issued a press release providing an updating, stating that the patient in question "is in critical condition" and that "Neurogene no longer anticipates completing enrollment in the 1E15 vg cohort (low-dose cohort) of NGN-401 in the fourth quarter of 2024". On this news, Neurogene's stock price fell sharply during intraday trading on November 18, 2024. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP

Related News